US Patent

US8361500 — Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom

Formulation · Assigned to Opko Health Inc · Expires 2029-10-09 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects tablet formulations containing a specific salt of the drug Rolapitant Hydrochloride and methods of treatment using these formulations.

USPTO Abstract

Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.

Drugs covered by this patent

rolapitant-hydrochloride (ROLAPITANT HYDROCHLORIDE)

Patent Metadata

Patent number: US8361500
Jurisdiction: US
Classification: Formulation
Expires: 2029-10-09
Drug substance claim: No
Drug product claim: Yes
Assignee: Opko Health Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.